Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

Leuk Res. 2004 Feb;28(2):127-31. doi: 10.1016/s0145-2126(03)00185-1.

Abstract

We used three to six courses of 2-chlorodeoxyadenosine (2-CdA) (2-h infusion at 0.14 mg/kg per day x 5 days) given over a period of 3-36 months to treat four patients with aggressive systemic mast cell disease (SMCD) that was resistant to interferon-alpha (IFN-alpha). Treatment with 2-CdA resulted in a major response in two patients and a good partial response in one other patient (75% overall response). Treatment was well tolerated and duration of remission in responding patients ranges from 2 months to 4+ years since the completion of treatment with 2-CdA.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Bone Marrow Examination
  • Cladribine / administration & dosage*
  • Cladribine / therapeutic use
  • Disease-Free Survival
  • Drug Administration Schedule
  • Drug Resistance
  • Female
  • Humans
  • Interferon-alpha / pharmacology
  • Male
  • Mastocytosis / drug therapy*
  • Mastocytosis / pathology
  • Middle Aged
  • Remission Induction / methods
  • Treatment Outcome

Substances

  • Interferon-alpha
  • Cladribine